Business Context and Reporting Period
Company: Altimmune, Inc. (NASDAQ: ALT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a novel peptide-based GLP-1/glucagon dual receptor agonist currently in clinical development for obesity and metabolic associated steatohepatitis (MASH). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $20,000 | $426,000 |
| Net Loss | $(95.1) million | $(88.4) million |
| Research & Development Expenses | $82.2 million | $65.8 million |
| General & Administrative Expenses | $21.0 million | $18.1 million |
| Cash, Cash Equivalents, and Short-Term Investments | $131.9 million | $197.8 million |
| Accumulated Deficit | $(561.4) million | $(466.3) million |
| Net Cash Used in Operating Activities | $(79.8) million | $(75.8) million |
Note: Revenue consists primarily of government and foundation grants. The company has no product sales revenue.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 7.5% (from $88.4 million to $95.1 million) driven by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by 25% ($16.4 million). This was primarily due to a $27.4 million increase related to the ramp-up of the IMPACT Phase 2b trial for MASH, partially offset by the wind-down of the MOMENTUM Phase 2 obesity trial and the discontinuation of the HepTcell program.
- Program Discontinuation: In March 2024, the company announced the discontinuation of the HepTcell program due to insufficient Phase 2 trial response. A non-cash impairment charge of $12.4 million was recorded in 2023 for this asset; no such charge occurred in 2024.
- Revenue Decline: Revenue decreased by 95% as the company closed out remaining government contracts that provided the bulk of 2023 revenue.
- Liquidity: Cash and short-term investments decreased by approximately $66 million year-over-year, reflecting continued operational burn and investment activity.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Phase 3 Program: In November 2024, Altimmune successfully completed its End-of-Phase 2 meeting with the FDA and agreed on a Phase 3 registrational program for pemvidutide in obesity. The program includes four trials expected to enroll approximately 5,000 subjects.
- MASH Data: Patient enrollment for the IMPACT Phase 2b MASH trial was completed in September 2024, with top-line data expected in the second quarter of 2025.
- Capital Needs: Management believes current cash resources ($131.9 million) are sufficient to fund operations for at least twelve months from the filing date. However, the company anticipates needing additional capital to complete clinical trials and commercialize products.
Risks and Contingencies
- Profitability: The company has incurred significant losses since inception and anticipates continuing to incur losses for the foreseeable future. It may never achieve profitability.
- Capital Raising: Future capital requirements depend on clinical trial progress. Failure to raise additional capital could force delays or termination of development programs.
- Regulatory Approval: There is no assurance that pemvidutide will receive regulatory approval. Clinical trials are expensive, time-consuming, and uncertain.
- Competition: The obesity and MASH markets are highly competitive, with major players like Novo Nordisk and Eli Lilly having approved products or advanced candidates.
- Legal Proceedings: A securities class action and a shareholder derivative lawsuit filed in 2024 were dismissed without prejudice in late 2024 and early 2025, respectively.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $131.9 million cash balance against the projected costs of the four Phase 3 obesity trials and the ongoing MASH program.
- Phase 3 Design: Confirm the specific endpoints and enrollment targets for the four VELOCITY Phase 3 trials agreed upon with the FDA.
- IMPACT Trial Data: Monitor the release of top-line data from the IMPACT Phase 2b MASH trial, expected in Q2 2025, as a critical value inflection point.
- Capital Markets Activity: Track the company's at-the-market (ATM) offering program, which raised $10.0 million in 2024 and $30.2 million in subsequent events (Jan-Feb 2025), to assess dilution and funding strategy.
- Intellectual Property: Review the expiration dates of patents related to pemvidutide (ranging from 2032 to 2043) and the terms of the in-license agreement with Mederis Diabetes, LLC.